In addition to providing developmental medicine consultations for children referred locally, regionally, nationally, and internationally, the Meyer Center for Developmental Pediatrics has always ...

Collaborating over the years with colleagues in genetics, infectious disease, immunology, and the Children’s Nutrition Research Center, Meyer Center faculty have participated in numerous research ...

MORRISVILLE – Worldwide Clinical Trials of Morrisville has formed a strategic alliance with KinderPharm of Exton, Pa., to create what the two clinical research organizations (CROs) are calling the ...

The Developmental and Behavioral Pediatrics Program recently expanded its services to include treatment of adolescents up to age 21. The program is under the direction of Rose Mary Merola, MD, a ...

The US Food and Drug Administration (FDA) has issued new draft guidance for sponsors who are developing anti-infective drug products for the pediatric population. The draft guidance notes that ...

At The Children’s Hospital at Saint Peter’s University Hospital, the Developmental and Behavioral Pediatrics Program treats children and young adults up to age 21. The program is under the direction ...

On May 17, the U.S. Food & Drug Administration (“FDA”) issued two important draft guidance documents, which clarify the agency’s approach to requirements and incentives in the realm of pediatric drug ...

Nutrition plays a crucial role in the neurodevelopment of children between conception and age 2; however, more assistance is needed for families regarding breast-feeding and dietary support, according ...

The FDA has drafted new recommendations on the development of drugs to treat pediatric patients with HIV meant to be applied on a global scale. The FDA has drafted new recommendations for the ...

Around a child’s first birthday, parents and caregivers can often start noticing signs and behaviors that could point to developmental delay in their children, causing concern for their well-being.

Considerable attention has been directed recently toward the limited availability of effective, U.S. Food and Drug Administration (FDA)-approved drugs for children in the United States. (1) It has ...

Awarded a €2.5M European Innovation Council (EIC) Accelerator grant to prepare for Phase II development in pediatric Fragile X Syndrome (FXS) patients CONNECTA leads innovation in neurodevelopmental ...